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Abstract.  Constitutive gene expression of four compo- 
nents of the plasminogen  activating enzyme system, 
urinary and tissue-type plasminogen activator (u-PA 
and t-PA),  plasminogen  activator inhibitor  1 (PAI-1) 
and PAI-2  in HT-1080 human fibrosarcoma cells, was 
modulated by the synthetic glucocorticoid dexametha- 
sone (Dex,  10  -7 M).  More than 90 % of u-PA, t-PA 
and PAI-1 antigen was found in conditioned medium, 
whereas PAI-2 was mainly cell associated.  In 48-h 
culture supernatants  (expressed per  106 cells) PAI-1 an- 
tigen increased from 350 to 3,300 ng and t-PA from 19 
to 38 ng.  u-PA and PAI-2 in the same samples de- 
creased from 380 to 46 ng and from 3.5 to  1.8 ng, 
respectively. Northern blot hybridization and nuclear 
"Run-on" transcription  assays demonstrated that the 
increase of t-PA and PAI-1 and the decrease of u-PA 
were associated with equivalent changes of gene tem- 
plate activity. Modulation of u-PA, t-PA and PAI-1 
gene expression by Dex was completely blocked by the 
glucocorticoid antagonist RU 38486,  suggesting that all 
effects were mediated through the glucocorticoid re- 
ceptor. Cycloheximide, an inhibitor of protein biosyn- 
thesis induced a  rapid transient increase of t-PA,  u-PA 
and PAI-1 mRNA and a  sustained increase of PAI-2 
mRNA, but blocked the more long term effects of 
Dex, suggesting that both constitutive and hormonally 
regulated maintenance  of mRNA steady state levels re- 
quired protein biosynthesis. 
p 
LASMINOOEr~ activators  (PAs)  1 are  highly  specific 
serine  proteases  of two genetically  distinct  types: 
t-PA and u-PA. They convert the abundant (200 mg/l) 
blood zymogen plasminogen  into  plasmin,  a  trypsin-like 
protease.  Natural  substrates  of plasmin are fibrin,  the solid 
protein matrix of the blood clot and a number of extracellular 
matrix  proteins (Collen,  1980; Saksela,  1985; Dano et al., 
1985). High PA activity is often associated with cells and tis- 
sues  involved  in  extracellular  matrix  degradation  in  the 
course of morphogenetic  events in ontogeny and malignant 
growth (Reich,  1978; Valinsky et al.,  1981; Markus,  1984; 
Dan0 et al.,  1985; Saksela,  1985). There  is considerable 
literature on developmental and hormonal control of PA bio- 
synthesis (Dano et al., 1985; Blasi et al.,  1987), whereas in 
this respect much less is known about the recently discovered 
PAls, PAI-1 (Loskutoff  et al., 1983; Van Mourik et al., 1984; 
Pannekoek et al., 1986) and PAI-2 (Astedt et al., 1985; Kopi- 
tar et al.,  1985; Chapman  and Stone,  1985; Kruithof et al., 
1986; Schleuning  et al.,  1987). It has previously been ob- 
served that the expression of PA activity by various  estab- 
lished cell lines,  primary cultures  and cultured tissues and 
organs  was suppressed  by glucocorticoids.  This  phenome- 
non was attributed to either a suppression of PA biosynthesis 
(Vassalli et al.,  1976; Werb,  1978; Hamilton  et al.,  1981; 
Coleman et al., 1982; Mira-y-Lopez  et al.,  1985; Littlefield 
L Abbreviations  used in this paper: Dex, Dexamethasone; PA, plasminogen 
activator. 
et al.,  1985; Mayer et al.,  1986), to an increase of PAI bio- 
synthesis (Seifert and Gelehrter,  1978; Crutchley et al., 1981; 
Coleman et al., 1982; Gelehrter et al.,  1983; Cwikel et al., 
1984; Andreasen et al.,  1986) or to a combination of both 
effects (Busso et al., 1987a; Pearson et al., 1987). PA activity 
or antigen changes  have been shown to be associated with 
respective  changes  in u-PA mRNA (Medcalf et al.,  1986; 
Busso et al., 1986; Pearson et al., 1987), t-PA (Busso et al., 
1987a) or PAI-1 (Andreasen et al., 1987) or gene template ac- 
tivities of u-PA (Collart et al.,  1987) and t-PA (Busso et al., 
1987b). A  synoptic  study however, addressing  the coordi- 
nated,  time-dependent  changes  of  secreted  and  cell  as- 
sociated antigen of all four factors, the associated changes in 
cellular mRNA levels and respective gene template activities 
and their dependence on protein biosynthesis has not previ- 
ously been performed. 
Materials and Methods 
Cell Culture and Harvesting of  Media 
HT-1080 cells were cultured to confluency using standard techniques in 150 
cm  2 culture flasks (Corning Glass Works, Coming, NY) in 40 ml DME 
containing 2 mM glutamine and 10% heat-inactivated FCS (Gibco, Paisley, 
UK). Before the start of an experiment, cells were maintained overnight at 
37~  in serum free DME. To start an experiment, medium was replaced 
with fresh serum free DME with or without 10  -7 M Dexamethasone (Dex, 
Sigma Chemical Co., St.  Louis, MO) prepared from a  stock solution of 
10  -3 M  in ethanol. Cells were subsequently maintained for various times 
￿9  The Rockefeller University Press, 0021-9525/88/03/971/8 $2.00 
The Journal of Cell Biology, Volume 106, March 1988 971-978  971 up to 48 h. Where indicated, cycloheximide (5 I~g/ml)  or the glucocorticoid 
antagonist RU 38484 (10  4  M) (Jung-Testas and Baulieu,  1983) was added 
to cell cultures 30 min or 14 h before the addition of Dex, respectively. (This 
concentration of RU 38486  was previously  determined to be optimal at 
blocking induction of PAI-I mRNA by  10  -7 M Dex).  To quantitate  PAI-2 
antigen, conditioned medium collected  at 24 and 48 h from nontreated  or 
Dex treated HT-1080 cells, was dialyzed overnight against deionized water 
at 4~  and concentrated 20-fold by vacuum centrifugation (Speed-vac, Sa- 
vant, Farmingdale,  NY) then stored at -30~  until further use. 
Activity Assay 
Plasminogen-dependent  fibrinolytic  activity in conditioned medium was de- 
termined by the Astrup plate assay  (Astrup and Miillertz,  1952). 
Preparation of  Cellular Extracts 
To quantify  cell associated  u-PA,  t-PA, PAl-1 and PAI-2, cells were har- 
vested after various incubation times by trypsinization, washed in 20 ml of 
PBS, centrifuged,  and then disrupted by adding 5 ml of 0.5 % ice cold NP-40 
lysis buffer (10 mM Tris-HCl, pH 7.4; 1(3 mM NaCI; 3 mM MgCIz; 1 mM 
EDTA;  0.1  mM PMSF;  1 mM DTT;  10  -6 M antipain (Sigma  Chemical 
Co. and 0.5%  NP-40),  vortexed,  and kept on ice for 5 rain. Nuclei  were 
sedimented and the supernatant containing the cellular extract was removed 
and stored at  -30~  until further use. 
Electrophoretic Procedures and Zymography 
HT-1080 cell-conditioned  medium obtained at various times from control 
and Dex-treated cultures was fractionated  by SDS-PAGE (Laemmli, 1970), 
using 10% separation gets. After electrophoresis,  ptasminogen activator ac- 
tivity in the gels was visualized by fibrin  zymography (Granelli-Piperno  and 
Reich,  1978). 
Antigen Determinations 
Conditioned medium was centrifuged to remove cellular debris and stored 
in aliquots at -30~  until further use. u-PA, PAI-I, and PAI-2 antigen were 
then determined by radioimmunoassay  as previously  described (Genton et 
al., 1987; Kruithof  et al., 1987). t-PA  antigen was determined using the Bio- 
pool IMULYSE 5 t-PA ELISA kit (Biopool,  Umea, Sweden),  according to 
manufacturers  instructions. 
D  NA Probes 
The Bgl II fragment of the pPA 11 4B cDNA clone, harboring a 1948 base 
pair (bp) insert of the human t-PA cDNA has been described (Fisher et al., 
1985). The t-PA cosmid clone, pPA cos 3 harboring the complete t-PA gene 
including  10 kb of flanking sequence was isolated by Dr, R. Fisher (Biogen 
Res.  Corp.)  from  a  cosmid  library  (Grosveld  et al.,  1982) and kindly 
provided. 
pUK 0321 (Schleuning, W.-D., L. Liebermann, and H. Mead, unpublished 
data) harboring a 1,023-bp fragment of the human u-PA cDNA was isolated 
from a cDNA library derived from human HT-1080 fibrosarcoma cells using 
mixed  oligonucleotide  probes  synthesized  according  to  a  published se- 
quence (Giinzler et al.,  1982). 
PAI-1 cDNA (1,500 base pair) and cosmid clones were isolated by Van 
den Berg et al., (1987) and Bosma et al., (1987), respectively,  and kindly 
provided. 
pPAI J7 harboring a 1,900 bp cDNA insert for PAI-2 was as described 
by Schleuning et al.,  1987. 
Metallothionein  lIa: Plasmid pH MT-I13  (Karin and Richards,  1982), was 
a kind gift from Dr.  Rob Richards,  Howard Florey  Institute  (Melbourne, 
Australia). 
Labeling of all probes with r  dATP was performed  by the random 
priming technique (Maniatis, et al., 1982). For the Run-on transcription as- 
say, each probe was linearized and fixed to nitrocellulose  as previously de- 
scribed (Greenberg and Ziff, 1984). 5 fag of DNA was applied  per slot (1 
lag for PAI-1). 
Northern Blot Analysis 
The isolation  of mRNA from cultured cells was performed as previously 
described (Medcalf et at.,  1986).  Agarose  gel  (0.9%) electrephoresis of 
mRNA in the presence of 20%  formaldehyde  followed by Northern blot 
transfer was performed as described by Thomas, (1980), but using Gene 
Figure 1. Zymographic analysis of HT-1080  cell-conditioned medi- 
um. Regions of plasminogen-dependent fibrinolytic activity in HT- 
1080 cell-conditioned medium were determined by zymographic 
analysis. Conditioned medium was collected at the indicated times 
(below) from control (A, B, C and D) or Dex treated (A" B; C; 
and D') HT-t080 cell cultures. A: 4 h; B: 8 h; C: 24 h; D: 48 h. 
Low molecular mass urokinase (31 kD) was used as a standard (far 
left lane). 110 kD t-PA/PAI-1 complexes, 54 kD u-PA and 31 kD low 
molecular mass urokinase positions are indicated to the right of the 
figure. 25 gl of medium, mixed with an equal volume of 2X sample 
buffer were charged per well.  Incubation time of SDS-PAGE gel 
with fibrin-agar underlay gel was 5  h. 
Screen  Plus membrane (New England Nuclear,  Boston,  MA) in place  of 
nitrocellulose filter paper. Hybridization conditions and processing of filters 
were performed as previously  described (Medcalf et al.,  1986). 
Run-on Transcription Assay 
The methods used were essentially  those described by Greenberg and Ziff, 
(1984). Cells were lysed in 10 ml of ice-cold NP-40 lysis buffer (10 mM Tris- 
HCI, pH 7.4; 10 mM NaCI; 3 mM MgCI2; 1 mM EDTA; 0.1 mM PMSF; 
1 mM DTT; 10  -6 M Antipain [Sigma Chemical Co., and 0.5% NP-40], the 
nuclei sedimented by centfifugation, resuspended  in glycerol storage buffer 
(Greenberg and Ziff,  1984), distributed into 100-~tl aliquots  (107 nuclei/ 
aliquot),  then snap frozen in liquid nitrogen and stored  at  -70~  As a 
negative control 1 p.1 of 1 mg/rnl ct-amanitin was added to replicate nuclear 
preparations (see figure legend) for 10 rain before the addition of the reaction 
buffer  (Greenberg and Ziff,  1984) while still  on ice.  Nuclear RNA was 
finally resuspended  in 300 ~tl hybridization buffer (50 mM Hepes; pH 7.4, 
0.3 M NaC1; 10 mM EDTA; 0.2 % SDS; 100 Ixg/ml yeast tRNA and 1  ￿  Den- 
hardts solution [Maniatis et al., 1982]) in sterile Eppendorf tubes. To quan- 
titate in vitro elongated u-PA, PAl-l,  PAI-2, t-PA, and metaUothionein lla 
transcripts, regions  of nitrocellulose filter  strips containing %lot-blotted" 
plasmid or genomic DNA (above), were cut out and prehybridized for 30 min 
at 65~  in prehybridizatiun buffer (50 mM Hepes,  pH 7.4; 0.3 M NaCI; 
10 mM EDTA; 0.2%  SDS;  1 mg/ml yeast tRNA and 5￿  Denhardts solu- 
tion), and then transferred  to the RNA samples in hybridization buffer pre- 
pared above. All filter strips containing eDNA slots were hybridized simul- 
taneously  for 36 h at 65~  then washed,  RNase  treated  (Greenberg and 
Ziff,  1984), air dried, and exposed  to x-ray film for up to 14 d. 
Densitometry 
Densitometric  analysis  of transcription and mRNA signals on autoradio- 
grams was performed using an LKB Ultroscan XL model 2222 densitome- 
ter (LKB-Pharmacia, Switzerland).  All calculations were expressed  rela- 
tive to an arbitrary value of I assigned to the intensity of the signal obtained 
for each sample at time point 0 unless otherwise stated (see figure legends). 
Results 
Dex-Mediated Modulation of  Fibrinolytic Activity 
and Antigen 
The  fibrinolytic  activity  of  HT-1080  cell-conditioned 
medium was 30 U/ml and 50 U/ml after 24 and 48 h culture, 
respectively (data not shown).  Treatment of the cells with 
Dex  suppressed  the  fibrinolytic activity below  detectable 
limits (0.1 U/ml). Analysis of PA activity by SDS-PAGE fol- 
lowed by zymographic analysis showed mainly one band at 
the position of u-PA (54 kD; Fig.  1), which was markedly 
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Figure 2. Quantitation of secreted 
and  cell  associated u-PA, t-PA, 
PAl-l, and PAI-2 antigen in HT- 
1080 cells. Conditioned medium 
was collected after 4,  8,  24,  or 
48 h  from  nontreated (t3), Dex 
treated  (e),  Dex  +  RU  38486 
treated  (,,)  or RU  38486 alone 
treated  (~)  HT-1080 cells. The 
effect of RU 38486 was not per- 
formed on secreted PAI-2 nor on 
antigen  levels  in  cell  lysates. 
Riffs for u-PA, PAl-l, and PAl-2 
and ELISA assay for t-PA antigen 
were performed as described in 
the text. Results presented repre- 
sent the average of at least 2 sepa- 
rate determinations. Inter and in- 
tra assay variations were less than 
5 % in all cases. All results have 
been expressed an ng antigen/106 
cells. 
reduced in conditioned medium of Dex treated cells. Minor 
bands  at  31  kD  (co-migrating  with  the  low  Mr  form  of 
u-PA), and at 110 kD were also visible, the latter representing 
a complex of t-PA with PAI-1 as demonstrated by immuno- 
precipitation (data not shown). 
Accumulation of secreted and cell associated u-PA, t-PA, 
PAI-1, and PAI-2 antigen in HT-1080 cells was determined af- 
ter 0, 2, 4,  8, 24, and 48 h exposure to Dex and is shown 
in Fig. 2. Expressed per 106 cells, secreted PAl-1 increased 
from 350 to 3,300 ng and t-PA from 19 to 38 ng.  u-PA and 
PAI-2  in the  same  samples  decreased from 380 to 46 ng 
and from 3.5  to  1.8 ng,  respectively. Modulation of u-PA, 
t-PA, and PAI-1 by Dex was completely blocked if cells were 
pretreated  overnight  with  the  glucocorticoid  antagonist 
RU  38486.  Cell  associated  u-PA  antigen  decreased  0.3- 
fold, whereas t-PA and PAI-2 increased 2-fold and 1.5-fold 
respectively. 
Time Dependent Effects on mRNA 
The association of Dex-mediated modulation of antigen with 
corresponding changes of mRNA was explored by Northern 
blot hybridization (Fig. 3, panels a, d, g, and  j). Quantitation 
of changes in mRNA was assessed by densitometric analysis 
of the  autoradiograms  (Fig.  3:  adjacent to the  respective 
mRNA panels).  Exposure times of all filters to autoradio- 
grams were chosen to visually optimize the signals present. 
u-PA mRNA was suppressed 95 % after 8 h (Fig. 3, A) as pre- 
viously described (Medcalfet al., 1986) and is included here 
as a control. Dex caused an ll.9-fold and a 7.8-fold increase 
in the 3.4 and 2.4 kb PAI-1 mRNA species respectively, after 
24 h (Fig. 3, panel G). Within a further 48 h, the 3.4 kb spe- 
cies decreased nearly 2-fold, whereas the 2.4 kb mRNA spe- 
cies increased 16-fold over basal levels, t-PA mRNA was con- 
stitutively expressed and  increased 3.4-fold (Fig.  3,  panel 
D). PAI-2 mRNA was present only at low concentration in 
control cells (exposure to the X-ray film: 15 d) yet suppressed 
50% after 2 h and virtually absent after 8 h (Fig. 3, panel 
J). Constitutive levels of all 4 mRNAs remained unchanged 
under serum-free conditions during a 48-h time course (see 
Fig. 4 and data not shown). Modulation of u-PA and PAI-1 
mRNA was prevented by pretreatment of the cells overnight 
with RU 38486 before addition of Dex (Fig. 4). 
Effects of Cycloheximide 
To determine whether on-going protein synthesis was  re- 
quired for constitutive or regulated gene expression, cells 
were treated with cycloheximide alone or before exposure to 
Dex. Fig. 3 (panels C, F, and I) demonstrate that cyclohexi- 
mide caused a transient augmentation of u-PA, t-PA and PAId 
mRNA within a 4-8-h period. The 3.4 kb species of PAI-1 
mRNA was most conspicuously increased (7.8-fold).  After 
8 h, however, the three mRNAs were reduced. The combina- 
tion of both Dex and cycloheximide caused a transient 9-fold 
and 4.5-fold increase in the 3.4 and 2.4 kb PAId mRNA spe- 
cies, respectively (Fig. 3, panel H). Hence protein biosyn- 
thesis was required for the glucocorticoid-mediated induc- 
tion of PAId  and t-PA mRNA  and the downregulation of 
u-PA mRNA. The effect of cycloheximide on PAI-2 gene ex- 
pression was peculiar: by itself it caused a sustained 7.8-fold 
increase in mRNA,  in  combination with  Dex a  transient 
fivefold increase of mRNA (Fig. 3, panels K and L). 
Effect on Gene Transcription Rates 
Fig. 5 (A) demonstrates the signals obtained from the Run-on 
transcription assays indicating the relative changes in tran- 
scriptional activity of u-PA, t-PA,  PAId, PAI-2, and metal- 
lothionein after treatment with Dex.  Quantitation of these 
signals by densitometric analysis is shown in Fig. 5 (B). It 
is  evident that urokinase gene template activity was  sup- 
pressed 50% after 2 h and was virtually absent after 4 h. t-PA 
and PAId gene transcription rates were increased 3.4 and 10- 
fold, respectively. Metallothionein IIa (Mt IIa) gene tran- 
scription, known to be activated by Dex (Karin et al.,  1980; 
Karin et al.,  1984)  was  used as a  positive control and is 
shown here to be transiently induced 50-fold. ~t-Amanitin, an 
inhibitor of RNA polymerase II was added to replicate nu- 
clear preparations (0 and 24-h time points) and was shown 
to block the transcriptional activity of PAI-1. ~t-Amanitin also 
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Figure 4.  Antagonism of RU 38486 on Dexamethasone induced 
modulation of  u-PA and PAI-1 mRNA in HT-1080  cells, mRNA  pre- 
pared from 24 hour nontreated (lane 1), Dex treated (lane 2), Dex 
plus RU 38 486 treated (lane 3) or RU 38486 alone treated (lane 
4) HT-1080  cell cultures was prepared and assessed by Northern 
blot hybridization for u-PA and PAI-1 mRNA as indicated. 4 Ixg 
mRNA was applied to each lane. 
blocked constitutive expression of u-PA and the induction of 
t-PA and metallothionein (data not shown). Changes of PAI-2 
gene transcription could not be determined accurately be- 
cause of the sensitivity limits of the assay.  Modulation of 
u-PA, t-PA and PAI-1 and MT-IIa gene transcription by Dex 
was blocked if cells were pretreated overnight with the glu- 
cocorticoid antagonist  RU  38486  (data  not  shown),  All 
changes in gene transcription corresponded to the respective 
changes in mRNA and antigen (cf. Figures 2,  3, and 5). 
Discussion 
Exposure of HT-1080 cells to Dex entailed a disproportionate 
increase of PAI-I and t-PA antigen, a decrease of u-PA and 
PAI-2 antigen and consequentially a net decrease of PA activ- 
ity in culture supernatants. Like in the human histiocytic cell 
line U-937 (Genton et al.,  1987; Wohlwend et al.,  1987) and 
in contrast to the other factors, PAI-2 was mainly cell as- 
sociated.  The peculiar pathway of PAI-2  biosynthesis and 
secretion, characterized by the coexistence of a nonglycosyl- 
ated intracellular and a glycosylated extracellular form (Gen- 
ton et al.,  1987) is therefore not an exclusive property of 
U-937 cells. 
The  relative amounts  of u-PA,  PAI-1, PAI-2,  and t-PA 
mRNA  changed concomitantly with antigen quantity. Ini- 
tially both the 3.4 and 2.4 kb PAI-1 mRNA species, (differing 
in the length of their 3'-untranslated region because of two 
poly-A addition sites  [Ny et al.,  1986;  Pannekoek et al., 
1986])  were induced.  Depending  on  time  after hormone 
treatment the smaller species became more abundant.  The 
Dex effect was transcriptional (see below) however the 2.4 
kb PAI-1 mRNA (lacking one of the TATTTAT  consensus se- 
quences conferring mRNA  instability  [Shaw  and  Kamen, 
1986]) was perhaps more stable. 
Cycloheximide caused a transient increase of u-PA, t-PA, 
and PAI-l(3.4 kb) mRNA and a sustained increase of PAI-2 
mRNA.  This finding  suggests that unstable protein inter- 
mediate(s)  which cause  under constitutive conditions the 
suppression of transcription or the degradation of mRNA 
must play a pivotal role in the regulation of mRNA steady 
state levels. A similar effect of protein synthesis inhibitors on 
modulating calcitonin-induced u-PA gene transcription and 
mRNA  stability  has  been  described  in  LLC-PKt  cells 
(Alms et al.,  1987). Furthermore, Klein et al., (1987), have 
demonstrated that ongoing protein synthesis is necessary for 
glucocorticoid regulation  of the  rat  at-acid  glycoprotein 
gene. Andreasen et al., (1987) recently reported that cyclo- 
heximide did not influence the induction of PAI-1 mRNA by 
Dex in HT-1080 cells. As only a single time point (16 h) was 
used in that study, none of the regulatory phenomena re- 
ported here were observed. The peculiar effect of cyclohexi- 
mide alone or in combination with DEX on PAI-2 mRNA 
is consistent with the interpretation that under constitutive 
conditions PAI-2 mRNA is rapidly degraded by protein fac- 
tor(s) with a limited half-life. The alternative interpretation 
would imply that constitutively expressed PAI-2 is regulated 
by a labile transcriptional suppressor and/or that Dex had a 
negative effect on PAI-2  mRNA stability.  This second hy- 
pothesis appears less attractive in the light of what is now 
known  about  glucocorticoid hormone action  (Yamamoto, 
1985). 
The constitutive template activity of the u-PA gene de- 
creased after exposure to Dex. As the Run-on transcription 
experiment was performed in the absence of cycloheximide, 
there is the possibility that Dex may be having an indirect 
effect on the u-PA gene. It has previously been shown that 
the suppressive action of Dex on u-PA mRNA in the human 
mammary cell line HBL-100 required on-going protein bio- 
synthesis (Busso, et al.,  1986). From the Northern blot data 
presented in this study, it is evident that on-going protein bio- 
synthesis is indeed required to maintain steady state levels of 
both u-PA, t-PA and PAI-1 mRNA. Although Dex suppressed 
u-PA gene transcription within a 2-h period, it is neverthe- 
less a  possibility that on-going protein biosynthesis is re- 
quired  for this  effect,  Furthermore,  cycloheximide when 
added alone also suppressed constitutive u-PA and t-PA gene 
transcription over a  48-h period,  and transiently induced 
PAI-1 gene transcription (data not shown). 
The effect of Dex was inhibited by the glucocorticoid an- 
tagonist  RU  38486  and  therefore  most  likely  mediated 
through the glucocorticoid receptor. Hence the u-PA gene 
Figure 3. Time course of u-PA, t-PA, PAI-1, and PAI-2 mRNA accumulation in HT-1080  cells, mRNA prepared from nontreated (0 h) cells, 
or from cells treated with Dex alone, Dex plus cycloheximide  (cyclohex), or with cycloheximide  alone for 2, 4, 8, 24, and 48 h was assessed 
by Northern blot analysis. Relative changes of u-PA, t-PA, PAl-l, and PAl-2 mRNA were determined by hybridization to random primer 
labeled u-PA, t-PA, PAl-l, or PAl-2 cDNA probes of similar specific activity. 4 ktg mRNA was applied in each lane. Arrows next to panels 
b, e, h, and k represent 28 S and 18 S ribosomal RNA markers. Exposure times of the filters to X-my film were chosen to visually optimize 
the signals present. Panels A-D and F-I and K and L were exposed to X-ray film overnight, E for 2 d, and J for 15 d. Quantitation of  changes 
of  u-PA, t-PA, PAI-t (3.4  and 2.4 kb species) and PAI-2 mRNA are indicated in the graphs adjacent to the respective mRNA panels. Changes 
in relative intensity of the signals presented were quantified by densitometric analysis by assigning an arbitrary score of 1 to the intensity 
of  the mRNA signal obtained at the zero point time for each component. Quantitation of  PAl-2 mRNA after treatment with Dex + cyclobexi- 
mide (cyclo) and with cycloheximide alone was calculated from the arbitrary score being assigned to the 2-h time point. 
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Figure 5. (A) Time course of Dex-induced modula- 
tion  of  u-PA,  t-PA,  PAI-1, PAI-2,  and  metal- 
lothionein  gene transcription.  HT-1080 cell nuclei 
were prepared  from nontreated  (0  h)  cells,  and 
from ceils treated for 30 min 2, 4, 8, 24, or 48 h 
with  Dex.  Elongation  and  labeling  of initiated 
RNA transcripts  in isolated  nuclei and hybridiza- 
tion to immobilized cDNA (u-PA, metallothionein 
[Met], and PAI-2) or genomic (t-PA and PAl-l) slot 
blots was performed as described in the materials 
and  methods  section.  r  was  added  to 
replicate nuclei aliquots at time 0 and 24 h and as- 
sessed  simultaneously  during  hybridization  for 
PAI-1 transcripts.  Exposure times were chosen to 
visually optimize the  signals  present:  u-PA  and 
metallothionein,  14 d; t-PA and PAl-l,  overnight; 
PAI-2,  10  d.  (B)  Quantification  of changes  in 
u-PA, t-PA, PAI-1 and metallothionein  gene tran- 
scription.  Changes in relative  intensity of the sig- 
nals presented in A were quantified by densitomet- 
ric analysis of the autoradiograms  described in the 
legend to Fig.  3. 
probably  contains  a  cis-acting,  glucocorticoid responsive, 
negative regulatory element. Such an element has been iden- 
tified  in the  regulatory region of the proopiomelanocortin 
gene (Charron and Drouin,  1986).  The respective findings 
on Dex modulation of t-PA and PAI-I gene transcription on 
the other hand,  suggest in contrast the presence of positive 
regulatory elements, possibly similar to those identified and 
studied  in  considerable  detail  in  other  genes  (Yamamoto, 
1985).  We note here that the Dex stimulation of PAI-1 gene 
template activity, although clearly observed in five consecu- 
tive experiments,  was in terms of intensity and time depen- 
dence more variable than the other effects. Time dependence 
of PAI-1 mRNA induction by Dex was also slightly variable 
although the magnitude of the induction was always consis- 
The Journal of Cell Biology, Volume 106,  1988  976 tent. PAId biosynthesis is modulated by factors present in se- 
rum like TGF-13 (Laiho et al.,  1986;  Lund et al.,  1987) and 
it is possible that variations in the quality of serum accounted 
for some of the differences observed. Furthermore, we can- 
not exclude that Dex also affects PAI-1 mRNA stability  as in 
the case of growth hormone (Pael and Axel,  1987),  in addi- 
tion to the effect on transcription  as the appropriate  experi- 
ments  to  rigorously  rule  out  such  a  possibility  were  not 
performed. 
Our  results  demonstrate  that  the  PA  enzyme  system  is 
modulated by glucocorticoids via negative and positive regu- 
lation of transcription.  Both, constitutive and regulated tran- 
scription are dependent on unstable protein factors  which 
may include the glucocorticoid receptor.  Although the net 
effect of glucocorticoid in our experimental system was a de- 
crease of PA activity,  the surprising  finding of positive regu- 
lation of t-PA and negative regulation of PAI-2,  precluded 
any  generalizations.  The glucocorticoid receptor is widely 
distributed and the observed mechanisms are therefore likely 
to operate in many cells and tissues. With the data in mind 
however that other workers have obtained by studying differ- 
ent cell lines or tissues, it appears likely that other hormonal, 
tissue  specific  or  developmentally  programmed  pathways 
must cooperate with the mechanisms described in this study. 
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